J Cancer 2017; 8(9):1673-1678. doi:10.7150/jca.19463

Research Paper

Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

Paul Zarogoulidis1✉*, Haidong Huang3*, Chong Bai3*, Dimitris Petridis4, Susana Papadopoulou5, Eleni Faniadou1, Ellada Eleftheriadou1, Georgia Trakada6, Kosmidis Cristoforos7, Aggeliki Rapti8, Lonny Yarmus9, David-Feller Kopman9, Yan-Gao Man10, Wolfgang Hohenforst-Schmidt2*

1. Pulmonary Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
2. Medical Clinic I, ''Fuerth'' Hospital, University of Erlangen, Fuerth, Germany;
3. Department of Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China;
4. Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece;
5. Department of Nutrition and Dietetics, Alexander Technological Educational Institute, Thessaloniki, Greece;
6. Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece;
7. General Surgery Department, European Interbalkan Medical Center, Thessaloniki, Greece;
8. Second Pulmonary Clinic, 'Sotiria' Chest Diseases Hospital, Athens, Greece;
9. Division of Pulmonary and Critical Care Medicine, Sheikh Zayed Cardiovascular & Critical Care Tower, Baltimore, U.S.A;
10. Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
* Paul Zarogoulidis, Wolfgang Hohenforst-Schmidt, Haidong Huang and Chong Bai contributed equally to this work.

Abstract

Introduction: Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patients that received only best supportive care. Results: The median life of patients at the date of disease progression, although increased by the administration of the drug (92 days versus 70) was not confirmed statistically significantly (Mann-Whitney test: W = 280, p = 0.138). The administration of drug seems to keep stable the biological condition of patients (McNemar's test: χ2 = 0.033, p = 0.99). Patients with chemotherapy the death rate was increased by 50% as compared to those with best supportive care (12 vs 8), the median life until the unfortunate event surpassed statistically significantly the latter (150 days of life as compared to 108, Mann-Whitney test: W = 57.5, p = 0.045). Discussion: Nab-paclitaxel as a monotherapy could be considered as a first line treatment option for patients > 75 years of age without any previous cardiological medical history when compared to best supportive care.

Keywords: NSCLC, nab-paclitaxel, Abraxane, adenocarcinoma, squamus, chemotherapy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zarogoulidis P, Huang H, Bai C, Petridis D, Papadopoulou S, Faniadou E, Eleftheriadou E, Trakada G, Cristoforos K, Rapti A, Yarmus L, Kopman DF, Man YG, Hohenforst-Schmidt W. Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old. J Cancer 2017; 8(9):1673-1678. doi:10.7150/jca.19463. Available from http://www.jcancer.org/v08p1673.htm